Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders.
Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders.
复制标题
DOI：
10.1002/ana.24506
复制
发表时间：
2015-11
影响因子：
11.2
通讯作者：
Koga, Yasutoshi
中科院分区：
文献类型：
--
作者：
Yatsuga, Shuichi;Fujita, Yasunori;Ishii, Akiko;Fukumoto, Yoshihiro;Arahata, Hajime;Kakuma, Tatsuyuki;Kojima, Toshio;Ito, Masafumi;Tanaka, Masashi;Saiki, Reo;Koga, Yasutoshi
线粒体疾病（MD）的诊断有时很困难，因为患者通常表现出由每个器官功能不全引起的单独或组合症状，这可能是呼吸链酶缺乏的结果。据报道，MD患者血清中的生长分化因子15（GDF-15）升高。在这项研究中，我们研究了GDF-15是否是比几种传统生物标志物更有用的MD生物标志物。我们测量了日本48名MD患者和146名健康对照者的GDF-15和成纤维细胞生长因子21（FGF-21）以及其他生物标志物的血清水平。通过酶联免疫吸附试验测定GDF-15和FGF-21浓度，并与乳酸、丙酮酸、肌酸激酶和乳酸/丙酮酸比值进行比较。我们计算了敏感性和特异性，并基于两个评分量表（包括纽卡斯尔线粒体疾病评分量表（NMDAS））评估了相关性。MD患者的平均GDF-15浓度是健康对照的6倍（2，711 ± 2，459 pg/ml vs 462.5 ± 141.0 pg/mL; p < 0.001）。使用受试者工作特征曲线，GDF-15的曲线下面积显著高于FGF-21和其他常规生物标志物。我们的数据表明，GDF-15是检查的生物标志物中最有用的MD生物标志物，并且与MD严重程度相关。我们的研究结果表明，GDF-15的测量是指示患有线粒体呼吸链缺陷的患者的最有用的一线测试。神经病学年会2015;78：神经病学年会2015;78：679-696
The diagnosis of mitochondrial disorders (MDs) is occasionally difficult because patients often present with solitary, or a combination of, symptoms caused by each organ insufficiency, which may be the result of respiratory chain enzyme deficiency. Growth differentiation factor 15 (GDF‐15) has been reported to be elevated in serum of patients with MDs. In this study, we investigated whether GDF‐15 is a more useful biomarker for MDs than several conventional biomarkers. We measured the serum levels of GDF‐15 and fibroblast growth factor 21 (FGF‐21), as well as other biomarkers, in 48 MD patients and in 146 healthy controls in Japan. GDF‐15 and FGF‐21 concentrations were measured by enzyme‐linked immunosorbant assay and compared with lactate, pyruvate, creatine kinase, and the lactate‐to‐pyruvate ratio. We calculated sensitivity and specificity and also evaluated the correlation based on two rating scales, including the Newcastle Mitochondrial Disease Rating Scale (NMDAS). Mean GDF‐15 concentration was 6‐fold higher in MD patients compared to healthy controls (2,711 ± 2,459 pg/ml vs 462.5 ± 141.0 pg/mL; p < 0.001). Using a receiver operating characteristic curve, the area under the curve was significantly higher for GDF‐15 than FGF‐21 and other conventional biomarkers. Our date suggest that GDF‐15 is the most useful biomarker for MDs of the biomarkers examined, and it is associated with MD severity. Our results suggest that measurement of GDF‐15 is the most useful first‐line test to indicate the patients who have the mitochondrial respiratory chain deficiency. Ann Neurol 2015;78:Ann Neurol 2015;78:679–696
登录
查看更多内容
DOI：
10.1016/s1474-4422(11)70155-7
发表时间：
2011-09
期刊：
The Lancet. Neurology
影响因子：
--
作者：
Suomalainen A;Elo JM;Pietiläinen KH;Hakonen AH;Sevastianova K;Korpela M;Isohanni P;Marjavaara SK;Tyni T;Kiuru-Enari S;Pihko H;Darin N;Õunap K;Kluijtmans LA;Paetau A;Buzkova J;Bindoff LA;Annunen-Rasila J;Uusimaa J;Rissanen A;Yki-Järvinen H;Hirano M;Tulinius M;Smeitink J;Tyynismaa H
通讯作者：
Tyynismaa H
成纤维细胞生长因子 21 受未折叠蛋白反应的 IRE1 α-XBP1 分支调节并抵消内质网应激诱导的肝脂肪变性
影响因子：
4.8
作者：
Jiang, Shan;Yan, Cheng;Jia, Wei-ping
通讯作者：
Jia, Wei-ping
影响因子：
9.9
作者：
Davis, Ryan L.;Liang, Christina;Sue, Carolyn M.
通讯作者：
Sue, Carolyn M.
影响因子：
4.8
作者：
Jousse, Celine;Deval, Christiane;Fafournoux, Pierre
通讯作者：
Fafournoux, Pierre
影响因子：
4.1
作者：
Luisa De Sousa-Coelho, Ana;Marrero, Pedro F.;Haro, Diego
通讯作者：
Haro, Diego